Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Radiation Medical Countermeasure Product Development

    By Global Biodefense StaffMarch 24, 2014
    Share
    Facebook LinkedIn Reddit Email

    The effects of radiation on the body may appear within minutes or develop many years after exposure. Radiation injury is directly proportional to the dose absorbed by the body and radiosensitive tissues.

    Depending on the dose of whole-body or partial-body exposure to external radiation, the effects can range from an increased risk of cancer years after exposure to more acute effects, including transient nausea and vomiting; hematopoietic and gastrointestinal injury, leading to immunosuppression and infection; metabolic abnormalities; hemorrhage and anemia; damage to the cardiovascular, pulmonary, and central nervous systems; and death.

    To counter such threats, the National Institute of Allergy and Infectious Diseases (NIAID) is seeking to support research and development of radiation and nuclear medical countermeasures towards licensure or approval. The supported work will encompass work performed in the drug development pathway as well as the administrative foundation necessary to facilitate and coordinate these activities in partnership with NIAID.

    NIAID has issued a solicitation to re-compete a contract for provision of services, facilities, expertise and capabilities for the development of radiation/nuclear medical countermeasures (MCMs) for the mitigation or treatment of acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE).

    The contractor will not identify or conduct basic research on new medical countermeasures. NIAID anticipates that products selected by the government for screening, testing, and development will come from industry, academia, and government agencies. The work to be performed under this contract will be initiated by NIAID and possibly include:

    • Animal models of radiation injury;
    • MCM testing in animal models of radiation injury;
    • The spectrum of existing and planned Investigational New Drug (IND)-enabling product development support services

    One Indefinite Delivery, Indefinite Quantity (ID/IQ) type contract is anticipated to be awarded to an organization to provide the comprehensive suite of product development services. The anticipated period of performance will start in or around July 2015 and continue for 5 years.

    Further details are available under Solicitation Number: HHS-NIH-NAID(AI)-SBSS-14-005.

    Animal Models Radiation
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – March 23, 2014
    Next Article Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

    Related Stories

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023

    Phase 2 Clinical Trial for Marburg Vaccine Starts in Uganda

    October 19, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.